Physician profile
Ting Li
NPI 1023005667
$1,454.10
in general payments reported to CMS, 2019-2025
11 companies · $264 in 2025
The $264 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $84.52 · 2020: $99.99 · 2021: $125 · 2022: $197 · 2023: $399 · 2024: $285 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $947.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $451.03 | 2022-2025 | Cardiomems, Mitraclip |
| Novartis Pharmaceuticals Corporation | $226.23 | 2019-2025 | |
| Astellas Pharma US INC | $199.98 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $157.27 | 2023-2025 | Eliquis, Camzyos |
| Medtronic, INC. | $132.78 | 2024 | Symplicity G3 |
| Astrazeneca Pharmaceuticals Lp | $77.82 | 2023-2024 | Farxiga |
| Pfizer INC. | $74.18 | 2022-2025 | |
| Amgen INC. | $64.50 | 2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.94 | 2021 | |
| Lilly USA, LLC | $23.67 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $21.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ting Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.